In the News
‘Gene-dose’ effect for Alzheon’s ALZ-801, a drug targeting Alzheimer’s disease
Closely-held US biotech firm Alzheon has announced the publication of data that shows for the first time a ‘gene-dose’ effect for a drug targeting Alzheimer’s disease to [...]
A Little-Known Drug Company Could Have The Answer For Some Alzheimer’s Patients
Alzheon plans to start a multi-center (U.S. and international) Phase 3 trial in 500 mild APOE4/4 homozygous patients next year, with a second trial to start [...]
Alzheimer’s biotech Alzheon to move once-failed drug into new PhIII
Tramiprosate, like so many others, could have been consigned to the scrap heap of once-promising AD meds that didn’t quite make the grade, never to be [...]
Alzheon Highlighted as One of the “Top 20 Life Science Startups to Watch in the U.S.”
Alzheon is focused on developing treatments for patients with Alzheimer’s disease and other neurological and psychiatric disorders. The company’s lead clinical product candidate, ALZ-801, is an [...]
Alzheon Gets $10M to Take Castoff Alzheimer’s Drug Into Pivotal Test
Run by a veteran of drug R&D for Alzheimer’s disease, Alzheon is betting that a smart trial design and a little chemistry work could [...]
Alzheimer’s startup Alzheon bags $10M and beats a path to Phase III
The veteran Alzheimer's researchers at Alzheon believe their novel treatment for the disease has a chance to come through where so many others have failed. Alzheon's [...]
Lexington’s Alzheon gives its own Alzheimer’s news to rival Biogen’s
While it’s the biggest, Biogen is not the only Bay State biotech presenting promising data for an Alzheimer’s drug this morning. The small Lexington-based biotech, Alzheon, [...]
Six drugs that could change the world
The strength of the state’s world-class drug developers is usually measured in terms of jobs and economics, rather than the effect on human health in coming [...]
Press Releases
Alzheon Awarded $47 Million Grant from U.S. National Institute on Aging for Phase 3 Clinical Study of ALZ-801, an Oral Treatment for Alzheimer’s Disease
Study to Evaluate ALZ-801 as a Precision Medicine Approach to Early Alzheimer’s Disease in Patients with APOE4/4 Genetic Profile Grant Supports Advancement of the First Oral [...]
Peer-Reviewed Scientific Publication Profiles First Wave of Disease-Modifying Alzheimer’s Treatments with Potential for Near Term Approval: Aducanumab, Gantenerumab, BAN2401 and ALZ-801
Anti-Amyloid Agents that Block Toxicity of Soluble Amyloid Oligomers – A Key Driver of Alzheimer’s Disease – Show Positive Clinical Effects and Consistent Biomarker Results Selectivity [...]
Alzheon Announces Appointments of Noel Dunn, Jordan Heller, and Diane Jorkasky, MD, to Board of Directors
FRAMINGHAM, Mass., January 7, 2020 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative [...]
Alzheon Announces Appointment of Peter N. Laivins as Head of Commercial Strategy and Planning
Industry veteran brings broad commercial expertise in neuroscience drug development and commercialization as Alzheon advances ALZ-801 into Phase 3 as potentially the first oral disease-modifying treatment [...]
Alzheon Publication Defines New Path for 2nd Generation Anti-Amyloid Drugs for Alzheimer’s Disease, Supporting Launch of Phase 3 Study with ALZ-801 Oral Tablet
Publication in Alzheimer's & Dementia, The Journal of the Alzheimer's Association, Details Scientific Underpinnings for ALZ-801 to Slow or Stop Disease Course Publication Outlines Therapeutic Characteristics [...]
Alzheon Presents Data on the Discovery of 3-SPA, an Endogenous Substance in the Human Brain, at the Alzheimer’s Association International Conference
3-SPA, also a Product of ALZ-801, Prevents Formation of Toxic Beta Amyloid Oligomers, the Key Driver of Alzheimer’s Disease FRAMINGHAM, Mass., July 14, 2019 – Alzheon, Inc., a [...]